Health Care's Sweet 16 Stocks: Johnson & Johnson vs. Pfizer
Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means Cinderella stories like Florida Gulf Coast have busted the brackets of would-be basketball prognosticators.
Here at The Motley Fool, we decided to stick with what we know, trading our basketball picks in for stock picks. We formed our own Sweet 16 filled with the top Big Pharma and Big Biotech stocks in a winner-take-all tournament is determined by the collective intelligence of our CAPS community.
This matchup will feature a heavyweight bout between Johnson & Johnson and Pfizer. Watch and find out which stock gets eliminated and which will advance to the next round.
Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson has its critics convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale or a well diversified giant that's perfect for your portfolio, check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.
The article Health Care's Sweet 16 Stocks: Johnson & Johnson vs. Pfizer originally appeared on Fool.com.Brenton Flynn has no position in any stocks mentioned. David Williamson owns shares of Pfizer. Follow him on Twitter: @MotleyDavid. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.